April 4 (Reuters) - Shionogi & Co Ltd:
* SHIONOGI & CO., LTD - TO PRESENT DATA SHOWING COVID-19 SYMPTOM RECURRENCE IS NOT ASSOCIATED WITH ENSITRELVIR TREATMENT
* SHIONOGI & CO., LTD - TIME TO FIRST NEGATIVE SARS-COV-2 CULTURE SHORTER WITH ENSITRELVIR 125 MG VERSUS PLACEBO IN PHASE 2B/3 PART OF SCORPIO-SR TRIAL
* SHIONOGI & CO., LTD - PLANS TO INITIATE A POST-EXPOSURE PREVENTION GLOBAL PHASE 3 STUDY, SCORPIO-PEP
* SHIONOGI & CO., LTD - ENSITRELVIR WAS WELL TOLERATED, AND NO NEW SAFETY CONCERNS WERE IDENTIFIED IN PHASE 2B/3 PART OF SCORPIO-SR TRIAL
* SHIONOGI & CO., LTD - ENSITRELVIR 125 MG SHOWED SIGNIFICANT REDUCTION FROM BASELINE VIRAL RNA ON DAY 4 OF PHASE 2B/3 PART OF SCORPIO-SR TRIAL Source text for Eikon: Further company coverage: